Fibrinolytic enhancement with a prostaglandin analogue iloprost.
Earlier workers have suggested a possible fibrinolytic effect using prostaglandin or prostaglandin analogues. Despite using maximum tolerated doses of the prostaglandin analogue Iloprost, we have been unable to demonstrate any significant effect on fibrinolysis in patients with stage IV peripheral vascular disease (Fontaine classification).
Berridge
D C
DC
University Hospital, Queen's Medical Centre, Nottingham.
Lonsdale
R
R
Jallihal
S
S
Westby
J C
JC
Hopkinson
B R
BR
Makin
G S
GS
D005342:Fibrinolysis / Q000187:drug effects*; D006801:Humans; D016285:Iloprost / Q000627:therapeutic use*; D007511:Ischemia / Q000097:blood / Q000188:drug therapy* / Q000503:physiopathology; D009336:Necrosis / Q000188:drug therapy; D016491:Peripheral Vascular Diseases / Q000097:blood / Q000188:drug therapy; D012871:Skin Diseases / Q000188:drug therapy
D016285:Iloprost